Moreover, our previous work discovered that EZH2 can suppress the IFN-γ signaling pathway by directly silencing the expression of interferon-γ receptor 1 (IFNGR1) [112] and ISG activation [113], which led to cancer cells being insensitive to IFN-γ treatment or resistant to trastuzumab treatment, respectively. Here, IFNG is linked to cancer.